UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 3, 2007
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-50513 |
|
13-3831168 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
15 Skyline Drive, Hawthorne, NY |
|
10532 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (914) 347-4300
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On July 6, 2007, Acorda Therapeutics, Inc. (the “Registrant”) announced that the underwriters of its June 2007 public offering of common stock have exercised their entire option to purchase an additional 562,500 shares of common stock at the public offering price of $18.50 per share. The exercise of the option increases the size of the offering to an aggregate of 4,312,500 shares of common stock.
The offering is being made pursuant to the Registrant’s shelf registration statement on Form S-3 (Registration No. 333-143348) filed with the Securities and Exchange Commission (the “Commission”) on May 30, 2007, including a related prospectus and prospectus supplement that the Registrant filed with the Commission on June 8, 2007.
The Registrant’s press release announcing that the underwriters have exercised their entire option is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
99.1 |
Press Release dated July 6, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Acorda Therapeutics, Inc. |
|||
|
|
|
|
|
|
July 6, 2007 |
By: |
/s/ David Lawrence |
|
|
|
|
Name: David Lawrence, M.B.A. |
|
|
|
|
Title: Chief Financial Officer |
|
3
Exhibit Index
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated July 6, 2007 |
4